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Epidemiological studies have reported a 40–50% reduction in
risk of developing colorectal cancer among chronic non-steroidal
anti-inflammatory drug (NSAID) users (Thun et al, 1991;
Giovannucci et al, 1994). Subsequent studies had implicated the
cyclo-oxygenase-2 (COX-2) enzyme, an inducible form of
prostaglandin synthase responsible for the conversion of arachi-
donic acid into prostaglandins, as the link between these observa-
tions (Dubois et al, 1998; Taketo, 1998). Notably, COX-2 is not
just a marker of inflammation but is actively involved in the
carcinogenesis process. Overexpression of COX-2 in colorectal
cancer has been associated with angiogenesis (Tsujii et al, 1998),
lymphatic invasion, metastasis (Tsujii et al, 1997) and poor prog-
nosis (Sheehan et al, 1999). In this context, COX-2 overexpression
is also frequently detected in gastric tumours (Ristimaki et al,
1997; Murata et al, 1999) as well as in premalignant gastric lesions
(Sung et al, 2000). Similar to colonic cancer, gastric tumours with
COX-2 over-expression appeared to have more frequent lymphatic
invasion (Murata et al, 1999). 
Nonetheless, the mechanism leading to COX-2 overexpression
in tumour remains elusive. A recent in-vitro study suggested that
wild-type p53, a major tumour suppressor gene that is involved in
the control of cell cycle progression, DNA integrity and cell
survival, inhibits the binding of TATA-binding proteins (TBP) to
the promoter region of Cox-2 gene (Subbaramaiah et al, 1999).
Thus, levels of prostaglandin E2 (PGE2) were 10-time lower in
cells with wild-type p53 than in those with mutated p53,
suggesting the potential interaction of p53 and COX-2 in cancer
cells. While both p53 mutation (Imazeki et al, 1992; Renault et al,
1993; Uchino et al, 1993) and COX-2 over-expression was
frequently reported in gastric cancers, their interactions had not
been properly evaluated. This study examined the correlation
between  p53 mutation and COX-2 expression in gastric cancer. 
MATERIALS AND METHODS 
Patients 
Patients with adenocarcinoma of stomach who had undergone
gastrectomy in the Prince of Wales Hospital of Hong Kong were
examined. A total of 39 patients were included (male:female =
21:18; median age of 69 years, ranges 29–80 years). 32 (82.1%)
cases had tumours located in the distal stomach and there were 7
(17.9%) cases of proximal cancer. 22 (56.4%) of these tumours
were intestinal type whilst the rest were classified as diffuse type
according to Lauren classification. Early gastric cancer as defined
by lesions confined to the gastric mucosa and submucosa was seen
in 4 cases. All patients were regularly followed up after surgery
(median 23 months, range 3–149 months). Survival was measured
from the time of surgery till death. 
COX-2 immunohistochemistry 
Archive pathological specimens were retrieved. 5-mm thick
formalin-fixed and paraffin – embedded gastrectomy sections was
retrieved. Sections were deparaffinized and endogenous perox-
idase activity was blocked with 3% H2O2 in Tris-buffered saline
(TBS). Non- specific binding was blocked with 5% rabbit serum
(DAKO, Glostrup, Denmark) in TBS, and the tissues were incub-
ated with antibody against COX-2 (1:100, Santa Cruz, Santa
Cruz, CA) in TBS containing 2% rabbit serum and 1% bovine
serum albumin. This was followed by sequential incubation with
biotinylated rabbit anti-goat immunoglobulins (1:400, DAKO)
and avidin–biotin peroxidase complex (DAKO) respectively.
Colour was developed in DAB solution (Sigma, St Louis, MO)
and counterstained with Mayer’s haematoxylin. Negative control
was performed by incubating samples without the primary anti-
body. 
COX-2 expression was scored semi-quantitatively according to
the percentage of positively stained tumour cells: grade 0 = no
expression, 1 = <10%, 2 = 10–30%, 3 = 30–60% and 4 = >60%
expression. A minimum of 10 high power view was used to assess
COX-2 expression level in tumour cells (Fig. 1). Positive staining
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independent investigators (KFT and TLL) who were blinded to the
p53 mutation statuses performed the assessment. The mean expres-
sion level (in percentage) was used in subsequent analysis. In
discordant cases (when inter-observer differences were greater than
30%), the two investigators would review the slides again. This
immunostaining result had been validated by in-situ hybridization
by using anti-sense COX-2 RNA probe (Sung et al, 2000). Over-
expression of COX-2 was defined as grade 2 or above expression. 
p53 mutation analysis 
The formalin-fixed, paraffin-embedded tissues were retrieved and
cut into 7 mm sections. Area containing cancer was carefully
microdissected. DNA extraction was performed by using High Pure
PCR Template Preparation Kit (Roche, GmbH, Germany) as
described by the manufacturer. Mutations in p53 were determined
by PCR-based single strand conformational polymorphism (SSCP)
of exons 5–8, where most mutations were detected. The primers
used for amplification were previously reported (Hse et al, 1991;
Okamoto et al, 1991). The PCR reaction mixtures contained 1 ´
PCR Buffer, 2.5 mM MgCl2, 0.1 mM of each dNTPs, 0.25 mM of
each primer, 0.625 U Taq polymerase (Gibco BRL, Rockville, MD),
and 1 ml of DNA template in a 25 ml reaction volume. Nested PCR
was performed and 0.3 ml (~3 mCi) of (a-32P)dCTP (NEN, MA) was
added into the second amplification. The MKN-45 human gastric
cancer cell line (Riken Cell Bank, Tokyo, Japan), that has wild-type
p53 (Matozaki et al, 1992), was included as normal control. 
For SSCP, 5 ml of the nested PCR products were mixed with 45 ml
of loading dye (95% formamide, 0.05% xylene cyanol and 0.05%
bromophenol blue). The mixture was heated to 95˚C for 10 minutes
and then put in ice immediately. A 4 ml aliquot was loaded
into 8% non-denaturing polyacrylamide gel with 5% glycerol.
Electrophoresis of the gel was carried out at room temperature for
18 hours. The gel was dried and exposed to X-ray film at 280˚C
with intensifying screen for 1 to 2 days. The presence of an
abnormal band shift when compared to wild-type control was noted.
Amplifications were repeated for samples showing band shifts to
ensure that consistent result were obtained. The shifted bands were
excised from the polyacrylamide gel and eluted by Milli-Q water.
Direct DNA sequencing was performed by using ABI Prism 310
Genetic Analyzer according to standard protocol (Perkin Elmer,
Branchburg, NJ). Both forward and reverse primers were used for
sequencing and all positive samples were repeatedly tested. 
Statistics 
All statistical calculations were performed by SPSS for Windows
software (version 9.0). Fisher exact test was used for categorical
data and Mann-Whitney U test was used in the comparison of
COX-2 expression between patients with and without p53 muta-
tion. Survival data was summarized by Kaplan-Meier curve and
compared by log-rank test. A P value (two-tailed) of less than 0.05
was considered statistically significant. 
RESULTS 
COX-2 expression 
30 (74.4%) cases of gastric tumours showed COX-2 expression
(grade 1 and above) while COX-2 overexpression (grade 2 and
above) was detected in 19 (48.7%) cases. Tumours with COX-2
over-expression had more lymph-node metastasis (78.9% versus
45%, P = 0.048). However, there was no significant difference in
demographic data, histological types and tumour locations
between tumours with and without COX-2 over-expression (Table
1). There was a trend towards better prognosis for tumours without
COX-2 overexpression (median survival 68.8 vs 28.8 months; log
rank test, P = 0.07; Figure 2). 
p53 mutation 
p53 mutation was detected in 20 tumours (51.3%). All mutations
were missense mutations leading to amino acid substitutions
(Table 2). Mutations in exon 5 were the most commonly detected
(60%), followed by mutations in exon 7 (25%). 18 (90%) of these
mutations were G:C ® A:T transition. Gastric tumours with
missense  p53 mutations had a significantly higher level of COX-2
expression than tumours with wild-type p53 (median scores: 3
versus 1, P = 0.016, Figure 3). There was no correlation between
p53 mutation and clinicopathological features of tumours
including age of patients, types of tumor, presence of lymph node
metastasis and survival (Table 1). 
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Figure 1 (A) A representative sample of diffuse type gastric cancer that
showed discohesive sheets of tumour cells (´400). Majority of cancer cells
(>60%, grade 4) exhibited strong cytoplasmic staining for COX-2 (dark
colour). (B) Intestinal type gastric cancer showing malignant glandular
pattern. More than 10% (grade 2) of tumour cells demonstrated COX-2
expression (dark colour staining). Arrows indicated some of the positively
stained cells (´400) 
BDISCUSSION 
The role of wild-type p53 protein is multiple and expression of
high level of p53 results in cell cycle arrest and apoptosis.
Furthermore, wild-type p53 could serve as a transcriptional
activator of genes containing the p53-binding sites as well as
inhibiting gene transcription (Ko and Prives, 1996). Thus, muta-
tions in the core domain of p53 may alter its binding ability and
affect its role in transcriptional regulation. One of the ways by
which p53 inhibits gene expression is via interaction with the
TATA-binding proteins (TBP) and thereby interfering with the
assembly of a functional transcription initiation complex (Seto et
al, 1992; Mack et al, 1993). Accordingly, a recent in-vitro study
demonstrated that wild-type p53 inhibits the formation of the
complex between TBP and human Cox-2 promoters in a cell-free
system (Subbaramaiah et al, 1999). Intuitively, p53 mutation
would result in loss of inhibitory effect on COX-2 expression in
human cancer. 
We showed that tumours with p53 missense mutation, which
leads to amino acid substitution, had a higher level of COX-2
expression when compared to tumours without p53 mutation. To
our knowledge, this is the first report of this correlation in human
cancer. In contrast to other tumour-related genes such as the onco-
genes of the ras family, mutations in ‘hotspot’ codons accounted
for only about 20% of all p53 mutations reported so far. As in this
study, mutation in codons 175 and 248 were detected in 3 cases
only (14.3%) and diverse mutation patterns were observed for the
remaining samples. Notably, most of these mutations were
G:C ® A:T transition as previously reported (Imazeki et al, 1992;
Renault et al, 1993). This transition has been linked to exposure to
nitrous oxide (Nguyen et al, 1992). On the other hand, with the
diverse mutation patterns, it is not difficult to anticipate the hetero-
geneous COX-2 expression level among tumours with different
p53 mutations. It would be interesting to study the in-vitro
promoter activity and responses by using reporter assays or DNA-
binding assays with various forms of p53 variants. 
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Table 1 Association of COX-2 expression and p53 mutation with clinicopathological features of gastric cancer 
COX-2 expression level p53 mutation 
2–4 (n = 19) 0–1 (n = 20) P Present (n = 20) Absent (n = 19) P
Median age 58 63 NSa 58 63 NS 
Male:female 10:9 11:9 NS 9:11 12:7 NS 
Histological type 
Intestinal 10 12 NS 11 11 NS 
Diffuse 9 8 9 8
Tumour location 
Distal 16 16 NS 15 17 NS 
Proximal 3 4 5 2
Early cancer 1 3 NS 2 2 NS 
Lymphatic involvement 15 9 0.048 15 9 NS 
aNS = not significant. 
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Figure 2 Kaplan–Meier curve of gastric cancer with and without COX-2
overexpression. The upper line represented tumours without COX-2
overexpression (grade 0 or 1) whilst the lower line indicated cancers with
COX-2 overexpression (median survival 28.8 months versus 68.8 months; 
P = 0.07, log rank test) 
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Figure 3 The scattergram of COX-2 expression in p53 mutated tumours
(mutant) versus tumours without wild-type p53 (wt). The horizontal line
represents the median value of COX-2 expression In this study, COX-2 expression was also detected in gastric
tumour with wild-type p53. This finding is not unexpected since
other factors are also involved in regulation of COX-2 expression.
For example, H. pylori-associated gastritis has been associated
with upregulation of COX-2 (Fu, 1999). This is turn may be trig-
gered by pro-inflammatory factors such as cytokines, tumour
necrosis factor-a, and nuclear factor-kB (Dubois et al, 1998).
Recently, the APC gene was also found to play a role in the trans-
lational regulation of COX-2 in colorectal cancer cell line (Hsi,
1999). Given the complexity of regulation of COX-2 expression,
wild-type p53 is probably just one of the many factors responsible
for the inhibition of COX-2 transcription in normal tissues. 
A modest increase in lymphatic involvement was detected
among tumours with COX-2 overexpression. In this regard, it is
not surprising to observe a trend towards lower survival in these
tumours when compared to tumours without COX-2 overexpres-
sion. Similar findings had been reported in colorectal as well as in
gastric cancer (Murata et al, 1999; Sheehan et al, 1999). Taken
together, these results suggested the prognostic significance of
COX-2 in gastrointestinal tumours and thus, COX-2 is probably
playing an active role in tumorigenesis and is not just an epiphen-
omenon. 
In conclusion, we have demonstrated that gastric tumours with
missense p53 mutations were associated with higher level of
COX-2 expression, suggesting the potential role of wild-type p53
in the regulation of COX-2 expression. Studies that look into the
regulation of COX-2 expression in cancer may offer a new insight
into gastric carcinogenesis and plausibly, chemoprevention path-
ways. 
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